AbbVie Strengthens US Manufacturing

AbbVie just announced it signed a definitive agreement to acquire a drug-delivery device manufacturing facility in Tempe, Arizona, plus associated intellectual property, from West Pharmaceutical Services. On 1/12/26, Abbvie presented the acquisition as a meaningful expansion of its drug-delivery device manufacturing capabilities and capacity. This follows similar construction projects in the North Chicago and Worcester, Massachusetts areas. On October 16th of last year, Abbvie disclosed plans to spend $10 billion over the next decade, and the Tempe site is the latest part of their larger commitment to invest in U.S manufacturing.

The numbers were not subtle. AbbVie said it plans to hire approximately 200 employees at the site and invest more than $175 million to acquire the facility, modernize it, and fully integrate it into AbbVie’s global manufacturing network. AbbVie also noted it already has a broad U.S. footprint — about 29,000 U.S. employees, including more than 6,000 across 11 U.S. manufacturing sites — and said the Arizona deal would expand its presence and economic impact in the state.

Strategically, AbbVie said the transaction supports production of current and next-generation immunology and neuroscience medicines, and that it includes the transfer of manufacturing facilities, including multiple production lines. Abbvie plans to use the Tempe location, among other things, for increasing production of their next gen, 3.5 mL on-body injector technology.

AbbVie said the transaction is anticipated to close in mid-2026, subject to closing conditions. Until then, investors can file this under more "supply-chain insurance" and Abbvie just following through on their 10-year-plan. While product breakthroughs are what usually get the spotlight, it’s the manufacturing and delivery systems that make sure those breakthroughs actually show up — preferably on time and in volume.

Disclaimer: This content is for informational and entertainment purposes only and does not constitute financial or investment advice. The information provided may be outdated or contain inaccuracies. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Investing involves risk, including the potential loss of principal. Unless explicitly stated otherwise, neither Equiscreen, LLC nor its beneficial owners hold any financial interest in the companies mentioned in our articles, and we do not receive compensation for including them. Equiscreen, LLC and its beneficial owners may buy or sell securities of any company referenced in our content at any time and without prior notice, and nothing published by Equiscreen, LLC should be interpreted as a recommendation to buy, sell, or hold any security. Any paid content or income-related materials will be clearly identified as “Sponsored” or “Advertorial,” and corresponding income disclosures can be found at the bottom of the page. For additional information, please contact [email protected].

Top Gainers

Top Losers

U.S. Commodities

2234 N Federal Hwy # 1022
Boca Raton, FL 33431

(561) 264-5726